Uncategorized FDA Approves Regeneron Pharmaceuticals, Inc. (REGN)’s Linvoseltamab for Multiple Myeloma Post Content
Uncategorized Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances Post Content
Uncategorized ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield™ Platform Post Content
Uncategorized Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition Post Content